南方财经5月29日电,今日,复星医药宣布,自主研发的1类新药芦沃美替尼片(商品名:复迈宁®;项目代号:FCN-159)正式获得国家药品监督管理局(NMPA)批准上市。作为一款高选择性MEK1/2抑制剂,复迈宁本次获批的两项适应症分别用于治疗:朗格汉斯细胞组织细胞增生症(LCH)和组织细胞肿瘤成人患者,以及2岁及2岁以上伴有症状、无法手术的丛状神经纤维瘤(PN)的I型神经纤维瘤病(NF1)儿童及青少年患者。复迈宁的双适应症获批填补了相关罕见肿瘤领域的治疗需求,为患者提供了新的治疗选择。(21世纪经济报道)
(文章来源:南方财经网)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.